Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ok op, i had three green stocks until you started up with jerry o! one of them was qlgc!
I'm following VPRT today. It tends to have pretty good swings, good trading.
What are you expecting out of SNDK today?
futures are looking like a run for the hills! who knows? maybe it's a wash out in the morning and a turnaround later in the day?
bought VPRT today:
VistaPrint Reports 2007 Fiscal Fourth Quarter and Full Fiscal Year Financial Results
* Fourth quarter revenue rose 60 percent year over year
* Full year revenue rose 68 percent year over year
* Full year GAAP fully diluted earnings per share rose 33 percent
year over year
* Full year non-GAAP fully diluted earnings per share rose 44 percent
year over year
* Acquired over 850,000 first-time customers during the quarter and
approximately 3 million during the fiscal year
tasr - didn't catch the low but bought yesterday at 14. and now holding up well.....hope it lasts!!
whatever happened to that day it went up 19 pts.? i miss the good old days!
only one green on my board today....old family-inherited at&t.
where do you think it's headed? zeev mentioned pretty high numbers toward the end of the year.
jerry, any opinion on sndk today? thanks
What have you heard about my QLGC?? Spread the news op!
i'm surprised they would reveal that information - did they??
maybe the whole video is now off topic! anybody care to guess at the share value for next week?
posted elsewhere, but interesting to hear this again:
http://release.theplatform.com/content.select?pid=Judmju1LP_5Q0qzXyBAXGtPWIQMp8i28
posted on iv....
http://www.cancercommentary.com/2007/06/03/provenge®-sipuleucel-t-and-prostate-cancer/
Provenge® (sipuleucel-T) and Prostate Cancer
by Gloria Gamat on June 3rd, 2007
The cancer immunotherapy Provenge® (sipuleucel-T) is currently being investigated in patients with early stage recurrent prostate cancer who have a rising serum prostate specific antigen (PSA) level, but whose cancer have not yet metastasized.
Results of the said study as presented by Oregon Health & Science University Cancer Institute revealed:
sipuleucel-T did not significantly delay the time it took for a patient’s PSA to reach a value of 3 ng/ml but it did show a prolongation in prostate-specific antigen doubling time (PSADT)
though not statistically significant, there was a trend observed in slowing the time to metastatic disease for patients who received sipuleucel-T against those who received placebo.
These findings have been presented Saturday, June 2, at 8 a.m. (CDT) at the 43rd Annual Meeting of the American Society of Clinical Oncologists (ASCO) in Chicago.
Manufactured by Dendreon Corporation, Provenge® (sipuleucel-T)’s safety and effectiveness in men with metastatic, androgen- independent prostate cancer (a different and more advanced patient population than those observed in this study) has recently been supported by an FDA advisory committee.
Once approved by the FDA, Provenge® (sipuleucel-T) would be the first FDA-approved treatment designed to train the body’s own immune system to fight cancer.
[FDA approval of Provenge® is expected very soon.]
Find more details from the full report.
funny that it doesn't rise 15 bucks like it lost 15 bucks (or whatever amount dropped on that infamous day)...but i'll take it!
march nytimes
...Dendreon tested Provenge in men who had prostate cancer that had spread to other parts of the body and was no longer being controlled by hormone therapy, but was also not causing symptoms. Roughly 50,000 men in the United States are in this category, and they generally survive only a year or two, Dr. Christopher Logothetis of M. D. Anderson Cancer Center, a consultant to Dendreon, told the panel.
Only one drug has been shown to lengthen the lives of these men: the chemotherapy drug Taxotere, also called docetaxel, which has extended survival by about two and a half months. But it has severe side effects, and many men opt not to use it.
In its main trial, Provenge extended median survival by 4.5 months — to 25.9 months for the treated patients versus 21.4 months for those receiving a placebo. After three years, 34 percent of patients who got Provenge were alive compared with 11 percent of those who got a placebo. Provenge also had generally mild side effects like fever and chills, though there was some signs it could raise the risk of strokes.
Still, skeptics on the committee pointed out that the main trial was small, only 127 patients. A second trial, even smaller, showed a survival advantage of 3.3 months, but that was not statistically significant.
Moreover, the goal of both trials had been to show that the drug stopped the advance of the cancer, which it did not. The F.D.A. reviewers raised questions about whether the survival results might have occurred just by chance.
So even as they voted that the drug looked effective, most panel members expressed some reservations.
Richard J. Chappell, a University of Wisconsin biostatistician and a committee member, voted against the drug’s efficacy. “I realize the need for hope,” Dr. Chappell said, “but I don’t want to give the hope on a false premise.”
Other panel members urged approval, especially given the novel nature of the treatment. “New fields are hard to foray into if we wait till everything’s perfect,” said Sharon Terry, a consumer representative on the committee.
About a dozen prostate cancer patients or advocates implored the committee to look past statistical rigidities and consider their plight.
“This kind of drug, Provenge, is all I can think of right now to give me hope,” said Steve Fleischmann of Seattle, who said he hoped to survive his prostate cancer to see his two young children grow up. “What is the harm of approving a drug that has been shown to let men live longer?”
To make the treatment, Dendreon mixes the patient’s immune system cells with a genetically engineered protein that is a combination of an immune booster and a molecule often found in prostate cancer cells but rarely elsewhere in the body. When the cells are put back into the patient’s body, they are thought to stimulate the immune system to attack any cells bearing the telltale molecule — meaning mainly the tumor. Three treatments are needed, two weeks apart.
http://www.nytimes.com/2007/03/30/health/30vaccine.html?ex=1180324800&en=607c47533447186e&ei...
Jerry,
Any opinion on QCOM if it wins the court ruling w/BRCM today?
thx
Motley Fool likes satellite radio...
http://www.fool.com/investing/high-growth/2007/05/23/xm-and-sirius-good-buy-or-good-bye.aspx
Patients rally to back Dendreon
http://seattletimes.nwsource.com/html/businesstechnology/2003714112_sundaybuzz20.html
Dendreon's prostate cancer drug has its own fan club — and it's a powerful one, too.
A coalition of five nonprofits across the country plans to stage a gathering in Washington D.C., on June 4 to protest the recent delay of Provenge by the U.S. Food and Drug Administration.
The FDA's decision May 8 to require more data on Provenge means the drug might not hit the market until 2010. As a result, the stock took a big hit.
While the nonprofits say their goal is mainly to raise awareness about prostate cancer and the lack of treatment options available, their initiative is called Provenge Now and is detailed on a Web site by the same name (www.provengenow.org).
The group hopes several thousand prostate-cancer survivors, patients and their families from across the U.S. turn out.
"The level of attention to this particular FDA decision is unlike any I've seen," said analyst Paul Latta of McAdams Wright Ragen in Seattle.
Already, one of the nonprofits, Malecare (www.malecare.com), has compiled about 2,000 signatures on a letter of protest that it will send to the FDA at the end of the month.
The FDA's outside panel of experts voted in March to endorse the drug. But on May 8 the agency said it won't approve the drug until further data on its efficacy is gathered.
Coalition leaders, in their bid to convince the FDA that it made a bad choice, met with the head of the FDA, Andrew von Eschenbach.
One of the nonprofits in the campaign — Us TOO in Olympia — is participating even though its governing rules forbid endorsing a drug or a product, Chairman Jim Kiefert said.
Us TOO has to be careful about how it addresses the issue. For example, instead of telling von Eschenbach that the FDA should approve Provenge, Us TOO will ask him to "follow the recommendations of your advisory committee," Kiefert said.
— Kirsten Orsini-Meinhard
George Soros buys 3m shares of BIVN.
if posted early today, my apologies
forbes/dendreon:
p://www.fool.com/investing/high-growth/2007/04/26/dendreon-is-worth-a-shot.aspx
Most recently, Bank of America analyst William Ho put the odds of approval of Provenge at 66%, with a $29 price target for Dendreon, based on interviews with FDA panel members and others in the industry. I am inclined to agree that the FDA is likely to approve Provenge, with the only condition being that post-marketing clinical data will need to be submitted and analyzed from an ongoing phase 3 trial of the drug.
The FDA will be under pressure to approve Provenge based on the positive recommendations. Some questions arose about a possible risk of strokes, but Provenge's unanimous safety endorsement from the advisory committee amounts to a pretty clean bill of health. Given the survival benefit and a desperate need for additional cancer therapies, the FDA may just give Provenge the benefit of the doubt and approve it for marketing -- even despite some controversial supporting data.
if posted early today, my apologies
forbes/dendreon:
p://www.fool.com/investing/high-growth/2007/04/26/dendreon-is-worth-a-shot.aspx
Most recently, Bank of America analyst William Ho put the odds of approval of Provenge at 66%, with a $29 price target for Dendreon, based on interviews with FDA panel members and others in the industry. I am inclined to agree that the FDA is likely to approve Provenge, with the only condition being that post-marketing clinical data will need to be submitted and analyzed from an ongoing phase 3 trial of the drug.
The FDA will be under pressure to approve Provenge based on the positive recommendations. Some questions arose about a possible risk of strokes, but Provenge's unanimous safety endorsement from the advisory committee amounts to a pretty clean bill of health. Given the survival benefit and a desperate need for additional cancer therapies, the FDA may just give Provenge the benefit of the doubt and approve it for marketing -- even despite some controversial supporting data.
Looks like RMBS may have some bad news or someone knows of impending good news and is trying to push it down to get cheaper shares...
i wasn't the 'back up the truck person'! just snoopin' around ihub as usual and found the back up the truck guy and then your response. thanks for responding.
i guess if you have children...a family...4 - 5 months is priceless.
...but will we turn green at the end of the day??
http://www.forbes.com/2007/04/09/dendreon-analyst-upate-markets-equity-cx_er_0409markets19.html?part...
DNDN
Rahul Jasuja, an analyst for MDB Capital Group, said it is difficult to predict how the FDA will vote. “There are two schools of thought. If you look at it one way, you have a product that failed its primary endpoint, and, given the FDA’s history with drugs that failed their endpoints, it should be rejected,” he said.
“But, this product is also a novel cancer drug for a hard to treat disease. It showed statistical significance in increasing survival and for oncology, survival should be the gold standard,” Jasuja said. In Dendreon (nasdaq: DNDN - news - people )'s initial trial, 34% of patients who took Provenge were alive after three years, compared with only 11% who took a placebo. (See : " Prostrate Drug Promise Vs. FDA Rigidity.")
hey jerry, there goes RMBS over 22.
thanks for your help this week jerry! i made some moola because of your postings.
nancie
(teacher on vacation....need the extra bucks!)
well, i just sold it here over 17. - a two-bagger + hope i did the right thing!
DNDN keeps making higher highs...can it last?
DNDN rockin'!
Anybody have RMBS news yet?
SNDK climbing it's way back...
RMBS moving a bit here....The restatement should be coming shortly??
Thanks for letting us know Zeev. I think I speak for the board when I say we will be thinking of you often and wishing you well. Cyber-vibes from cyber-friends are as good as any! We're sending our best to you.
All the best to you Zeev. We miss ya!
titan
I do not like RMBS. Just needed to get that out there.
big good or big bad? RMBS